Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Open access
Younes, Anas, Brody, Joshua, Carpio, Cecilia, Lopez-Guillermo, Armando, Ben-Yehuda, Dina, Ferhanoglu, Burhan, Nagler, Arnon, Ozcan, Muhit, Avivi, Irit, Bosch, Francesc, Caballero Barrigón, Maria Dolores, Hellmann, Andrzej, Kuss, Bryone, Ma, David D F, Demirkan, Fatih, Yağci, Münci, Horowitz, Netanel A, Marlton, Paula, Cordoba, Raul, Wrobel, Tomasz, Buglio, Daniela, Streit, Michael, Hodkinson, Brendan P, Schaffer, Michael, Alvarez, John, Ceulemans, Rob, Balasubramanian, Sriram, de Jong, Jan, Wang, Shean-Sheng, Fourneau, Nele, Jurczak, Wojciech · 2019 · The Lancet Haematology

Abstract

BACKGROUND Preclinical studies have shown synergistic antitumour effects between ibrutinib and immune-checkpoint blockade. The aim of this study was to assess the safety and activity of ibrutinib in combination with nivolumab in patients with relapsed or refractory B-cell malignant diseases. METHODS We did a two-part, open-label, phase 1/2a study at 21 hospitals in Australia, Israel, Poland, Spain, Turkey, and the USA. The primary objective of part A (dose escalation) was to assess the safety of daily oral ibrutinib (420 mg or 560 mg) in combination with intravenous nivolumab (3 mg/kg every 2 weeks) to ascertain a recommended phase 2 dose in patients with relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, or diffuse large B-cell lymphoma. Dose optimisation was investigated using a modified toxicity probability interval design. The primary objective of the part B expansion phase was to establish the preliminary activity (the proportion of patients who achieved an overall response) of the combination of ibrutinib and nivolumab in four cohorts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del17p or del11q), follicular lymphoma, diffuse large B-cell lymphoma, and Richter's transformation. All participants who received at least one dose of treatment were included in the primary analysis and analyses were done by disease cohort. This trial is registered with ClinicalTrials.gov, number NCT02329847. The trial is ongoing. FINDINGS Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]). INTERPRETATION The combination of ibrutinib and nivolumab had an acceptable safety profile and preliminary activity was similar to that reported with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma. The clinical response in patients with Richter's transformation was promising and supports further clinical assessment. FUNDING Janssen R&D.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2352-3026(18)30217-5

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 194

Metadata

Authors
Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, B., Nagler, A., Ozcan, M., Avivi, I., Bosch, F., Caballero Barrigón, M. D., Hellmann, A., Kuss, B., Ma, D. D. F., Demirkan, F., Yağci, M., Horowitz, N. A., Marlton, P., Cordoba, R., Wrobel, T., Buglio, D., Streit, M., Hodkinson, B. P., Schaffer, M., Alvarez, J., Ceulemans, R., Balasubramanian, S., de Jong, J., Wang, S.-S., Fourneau, N., & Jurczak, W.
Venue
The Lancet Haematology
Publisher
Elsevier BV
Published
2019-02
Volume
6
Issue
2
Pages
e67-e78
ISSN
2352-3026 (ISSN-L)
OpenAlex
W2910063137
Cited by
194
References
8
FWCI
12.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. https://app.cochat.ai/papers/10.1016/s2352-3026(18)30217-5
The paper
Younes, A., Brody, J., Carpio, C., Lopez-Guillermo, A., Ben-Yehuda, D., Ferhanoglu, B., Nagler, A., Ozcan, M., Avivi, I., Bosch, F., Caballero Barrigón, M. D., Hellmann, A., Kuss, B., Ma, D. D. F., Demirkan, F., Yağci, M., Horowitz, N. A., Marlton, P., Cordoba, R., . . . Jurczak, W. (2019). Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(18)30217-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.